Hyperprogression of advanced Melanoma Disease with Pembrolizumab adjuvant

被引：0
|
作者：
Geidel, G. [1 ]
Ammann, N. [1 ]
Schneider, S. W. [1 ]
Gebhardt, C. [1 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Dermatol & Venerol, D-20246 Hamburg, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2021年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
DK03/03
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [21] Spotlight on pembrolizumab in the treatment of advanced melanoma
    Rajakulendran, Thanashan
    Adam, David N.
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2883 - 2886
  • [22] Immune-mediated Ormond disease during adjuvant immunotherapy with pembrolizumab for malignant melanoma
    Belz, S.
    Hildebrandt, L.
    Haalck, T.
    Schneider, S. W.
    Gebhardt, C.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 103 - 103
  • [23] Advanced melanoma in adults: Pembrolizumab as a treatment option
    Silvinato, Antonio
    Bernardo, Wanderley Marques
    Floriano, Idevaldo
    [J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 (02): : 100 - 107
  • [24] Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review
    Rizzetto, Giulio
    De Simoni, Edoardo
    Molinelli, Elisa
    Offidani, Annamaria
    Simonetti, Oriana
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (15)
  • [25] Pembrolizumab increases survival in resected advanced melanoma
    不详
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (08) : 1676 - 1676
  • [26] Pembrolizumab versus Ipilimumab in advanced malignant Melanoma
    Bauer-Kemeny, Claudia
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2018, 143 (04) : 227 - +
  • [27] Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma
    Sullivan, Ryan J.
    Flaherty, Keith T.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (13) : 2892 - 2897
  • [28] COST EFFECTIVENESS OF PEMBROLIZUMAB AND IPILIMUMAB IN ADVANCED MELANOMA
    Lu, T.
    Hay, J. W.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A149 - A149
  • [29] Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
    Eggermont, Alexander M. M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew
    Lichinitser, Mikhail
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Maio, Michele
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Lorigan, Paul
    Ibrahim, Nageatte
    Marreaud, Sandrine
    van Akkooi, Alexander C. J.
    Suciu, Stefan
    Robert, Caroline
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19): : 1789 - 1801
  • [30] Challenging the standard of care in advanced melanoma: focus on pembrolizumab
    Abdul-Karim, Raghad M.
    Cowey, C. Lance
    [J]. CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 433 - 442
12345